当前位置: X-MOL 学术J. Label. Comp. Radiopharm. › 论文详情
Synthesis of imatinib, a tyrosine kinase inhibitor, labeled with carbon-14.
Journal of Labelled Compounds and Radiopharmaceuticals ( IF 1.809 ) Pub Date : 2020-02-05 , DOI: 10.1002/jlcr.3830
Julie Kang,Jun Young Lee,Jeong-Hoon Park,Dong-Jo Chang

Imatinib (Gleevec) is a multiple tyrosine kinase inhibitor that decreases the activity of the fusion oncogene called BCR-ABL (breakpoint cluster region protein-Abelson murine leukemia viral oncogene homolog) and is clinically used for the treatment of chronic myelogenous leukemia and acute lymphocytic leukemia. Small molecule drugs, such as imatinib, can bind to several cellular proteins including the target proteins in the cells, inducing undesirable effects along with the effects against the disease. In this study, we report the synthetic optimization for 14 C-labeling and radiosynthesis of [14 C]imatinib to analyze binding with cellular proteins using accelerator mass spectroscopy. 14 C-labeling of imatinib was performed by the synthesis of 14 C-labeld 2-aminopyrimidine intermediate using [14 C]guanidine·HCl, which includes an in situ reduction of an inseparable byproduct for easy purification by HPLC, followed by a cross-coupling reaction with aryl bromide precursor. The radiosynthesis of [14 C]imatinib (specific activity, 631 MBq/mmol; radiochemical purity, 99.6%) was achieved in six steps with a total chemical yield of 29.2%.
更新日期:2020-04-23

 

全部期刊列表>>
材料学研究精选
胸腔和胸部成像专题
自然科研论文编辑服务
ACS ES&T Engineering
ACS ES&T Water
屿渡论文,编辑服务
杨超勇
周一歌
华东师范大学
南京工业大学
清华大学
中科大
唐勇
跟Nature、Science文章学绘图
隐藏1h前已浏览文章
中洪博元
课题组网站
新版X-MOL期刊搜索和高级搜索功能介绍
ACS材料视界
x-mol收录
福州大学
南京大学
王杰
南科大
左智伟
湖南大学
清华大学
王小野
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug